

Molecular mechanism of inflammatory pain

Yeu-Shiuan Su, Wei-Hsin Sun, Chih-Cheng Chen

Yeu-Shiuan Su, Wei-Hsin Sun, Department of Life Sciences, National Central University, Jhongli 32054, Taiwan
Chih-Cheng Chen, Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan

Chih-Cheng Chen, Taiwan Mouse Clinic-National Phenotyping and Drug Testing Center, Academia Sinica, Taipei 115, Taiwan

Author contributions: Su YS and Sun WH contributed equally to this work, collected literatures, and wrote the manuscript; Chen CC designed the scope of the minireview and wrote the manuscript.

Supported by (In part) Intramural Funding from Academia Sinica; and by grants from the National Science Council, Taiwan (NSC 102-2325-B-001-042 to Chen CC; NSC 101-2321-B-008-001 to Sun WH)

Correspondence to: Chih-Cheng Chen, PhD, Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Section 2, Taipei 115, Taiwan. chih@ibms.sinica.edu.tw

Telephone: +886-2-26523917 Fax: +886-2-27829224

Received: June 29, 2013 Revised: September 27, 2013

Accepted: November 1, 2013

Published online: March 27, 2014

Abstract

Chronic inflammatory pain resulting from arthritis, nerve injury and tumor growth is a serious public health issue. One of the major challenges in chronic inflammatory pain research is to develop new pharmacologic treatments with long-term efficacy and few side effects. The mediators released from inflamed sites induce complex changes in peripheral and central processing by directly acting on transducer receptors located on primary sensory neurons to transmit pain signals or indirectly modulating pain signals by activating receptors coupled with G-proteins and second messengers. High local proton concentration (acidosis) is thought to be a decisive factor in inflammatory pain and other mediators such as prostaglandin, bradykinin, and serotonin enhance proton-induced pain. Proton-sensing ion channels [transient receptor potential V1 (TRPV1) and the acid-sensing ion channel (ASIC) family] are major receptors for direct excitation of nociceptive sensory neurons in response to acidosis or inflammation.

G-protein-coupled receptors activated by prostaglandin, bradykinin, serotonin, and proton modulate functions of TRPV1, ASICs or other ion channels, thus leading to inflammation- or acidosis-linked hyperalgesia. Although detailed mechanisms remain unsolved, clearly different types of pain or hyperalgesia could be due to complex interactions between a distinct subset of inflammatory mediator receptors expressed in a subset of nociceptors. This review describes new directions for the development of novel therapeutic treatments in pain.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Acid-sensing ion channel; Acidosis; G-protein-coupled receptor; Inflammation; Proton-sensing ion channel; Transient receptor potential V1

Core tip: Tissue acidosis that occurs during inflammation is central to the development and maintenance of chronic pain. Recent studies have revealed a variety of proton-sensing ion channels (*e.g.*, acid-sensing ion channels, transient receptor potential V1) and G-protein-coupled receptors (*e.g.*, G2 accumulation 2A, G-protein-coupled receptor 4, ovarian cancer G-protein-coupled receptor, T-cell death-associated gene 8) responsible for acid-induced pain. These cell-surface membrane proteins are promising therapeutic targets for the development of new analgesic drugs for chronic inflammatory pain.

Su YS, Sun WH, Chen CC. Molecular mechanism of inflammatory pain. *World J Anesthesiol* 2014; 3(1): 71-81 Available from: URL: <http://www.wjgnet.com/2218-6182/full/v3/i1/71.htm> DOI: <http://dx.doi.org/10.5313/wja.v3.i1.71>

INTRODUCTION

Cancer, nerve injury, and arthritis often cause chronic inflammatory pain^[1]. Chronic pain may have a profound

effect on a person's life and society when not effectively treated. Although a variety of pharmacologic treatments are available, they are limited by unacceptable side effects or short-term efficacy. The development of long-acting pharmacologic therapies requires knowledge of how chronic inflammatory pain signals are initially interpreted and subsequently transmitted and perpetuated. This review focuses on recent findings from studies of the molecular mechanisms of inflammatory pain transmission and modulation, especially the roles of mediator-gated ion channels and G-protein-coupled receptors (GPCRs).

INFLAMMATORY PAIN

When our body senses noxious stimuli (such as a cut from a sharp knife, burn from an open flame, or contact with burning or erosive chemicals), the signal quickly activates primary sensory afferents (nociceptors) and delivers a message to the brain to elicit the pain feeling. When stimuli are absent, the painful experience disappears. The situation is called acute pain because the pain signal is transient^[2]. Noxious stimuli activate transducer receptors located on medium myelinated (A δ) and small unmyelinated (C) nociceptors to induce the receptor potential. The receptor potential activates a variety of voltage-gated ion channels to transmit pain signals to secondary nociceptors in the dorsal horn of the spinal cord, then to the brain^[3].

If the tissues are damaged mechanically or by pathogen infection, autoimmune disease, or tumor growth, the sites of the damaged or infected tissues usually show inflammatory responses such as redness, swelling and heat accompanied by persistent pain; endogenous mediators released from the damaged or infected tissues increase the extravasation of the vessels and attract the immune cells, including mast cells, macrophages, neutrophils, and platelets, to the injured site for the inflammatory response^[1]. The "inflammatory soup" is rich in purines, amines, cytokines, protons, ions and growth factors. These mediators can directly activate the nociceptors, evoking pain or modulating the sensitivity of the primary nociceptors, thus causing a hyperreactive reaction to stimuli. As a result, normal stimuli such as a light touch or a brush are perceived as painful (allodynia), or normally painful stimuli cause pain of greater intensity (hyperalgesia)^[4]. In the periphery, inflammatory mediators bind to GPCRs to activate protein kinases A and C (PKA and PKC) to phosphorylate receptors or increase receptor expression, which enhances the sensitivity of primary nociceptors, called peripheral sensitization. Primary nociceptor-driven transmitter release activates intracellular kinases to phosphorylate receptors. This situation leads to an immediate and activity-dependent increase in the excitability and responsiveness of dorsal horn neurons, called central sensitization. Central sensitization could be sustained for some time because of transcriptional changes^[2,4].

INFLAMMATORY MEDIATORS OF PAIN

The endogenous mediators, such as prostaglandin E₂

(PGE₂), bradykinin (BK), serotonin [5-hydroxytryptamine (5-HT)], proton, histamine, and ATP, are released from the damaged site of the tissue and immune cells to induce inflammation and nociception^[2]. These mediators act on transducer receptors situated on sensory neurons to induce complex changes in peripheral and central signal processing. Although some mediators can act directly on ion channels to induce receptor potential, for the most part these chemical interactions occur through the activation of receptors coupled with G-proteins and second messengers, thus activating protein kinases. Such activated kinases phosphorylate ion channels to alter ion permeability or phosphorylate cellular proteins to increase gene expression.

Earlier studies of single mediators demonstrated that BK, PGE₂, 5-HT, and proton have excitatory action on cutaneous nociceptors and induces transient pain^[5-8]. More sustained effects are achieved only in a high-concentration (10^{-5} mol/L) combination of inflammatory mediators (BK, 5-HT, PGE₂, and histamine)^[9]. Steen *et al.*^[10] proposed that the combination of inflammatory mediators plays a role in sensitizing the low pH effect. The acidosis in inflamed tissues is the decisive factor for ongoing nociceptor excitation and sustained pain. However, the interaction between various mediators remains unclear.

TISSUE ACIDOSIS AND ACID-SENSING RECEPTORS

Tissue acidosis is a common phenomenon found in inflammation (reduced to pH 5.4)^[11], in lesions or incisions (reduced to pH 6.5)^[12], in ischemic heart or muscle (pH 5.7-7.0)^[13,14], and even in malignant tumors (pH 5.8-7.4)^[15]. High local proton concentrations in inflamed tissues can excite and sensitize rat skin nociceptors and can cause sustained pain in human skin^[7,16,17]. As well, the combination of inflammatory mediators (BK, 5-HT, PGE₂, and histamine) in acid solution (pH 6.1) can excite and sensitize rat skin nociceptors^[18]. Injections of the inflammatory mediator combination in neutral solution in human skin induces dose-dependent, transient, burning pain, but the effects become more intense and prolonged when the mediator combination is in acidic solution^[19]. Studies of rat dorsal root ganglion (DRG) neurons revealed that acidic solutions induced a cation conductance in a subset of neurons^[19], and a proton-activated sustained current is potentiated more by the mediator combination than each mediator alone^[20]. Proton-activated currents found in the sensory neurons are due to direct activation of the non-selective cation channels and indirect modulation of ion channels^[21]. Proton-gated ion channels and proton-sensing GPCRs expressed on nociceptors are potential candidates responsible for acidosis-induced pain.

PROTON-GATED ION CHANNELS: ACID-SENSING ION CHANNELS

Acid-sensing ion channels (ASICs), which belong to

the family of degenerin/epithelial amiloride-sensitive Na^+ channels, are voltage-insensitive cationic channels activated by extracellular protons^[22-25]. The ASIC family, comprising ASIC1a, ASIC1b, ASIC2a, ASIC2b, ASIC3, ASIC4 and ASIC5, is expressed in the peripheral and central nervous systems^[26-28].

Among ASICs, ASIC3 is the most sensitive receptor to protons, with pH 0.5 for activation around 6.7, and is expressed in both small- and large-diameter DRG neurons^[29-31]. The expression of ASIC3 in DRG is increased with hind paw inflammation in rats^[32,33]. As well, ASIC3 channel activity is enhanced by several components of the inflammatory soup, such as BK, 5-HT, hypertonicity, arachidonic acid, and nitric oxide^[34-38]. Thus, ASIC3 is considered a sensor of acidic and primary inflammatory pain^[34]. Study of skin nerves revealed that loss of ASIC3 increases the sensitivity of mechanoreceptors to light touch but decreases that of mechanoreceptors to a noxious pinch^[39,40]. Surprisingly, mice lacking the ASIC3 gene still respond to acid stimuli and have acid-induced pain or primary inflammatory pain^[39,41-43]. However, inhibiting ASIC3 function with a specific peptide or small interfering RNA significantly reduces cutaneous acidic pain under normal or inflammatory conditions and postoperative pain^[34,44].

Given that ASIC3 is predominantly expressed in muscle nociceptors rather than in cutaneous nociceptors^[45], ASIC3 should be required for development of secondary mechanical hyperalgesia induced by acid injection in skeletal muscle or by muscle inflammation^[46-48]. Although the ASIC3 requirement for development and maintenance of muscle inflammatory pain is argued, selective microRNA-targeted ASIC3 inhibits primary and secondary hyperalgesia induced by muscle inflammation^[49]. Interestingly, a recent study by Lin *et al.*^[50] suggested that ASIC3-mediated muscle pain is negatively modulated by substance P *via* regulation of the M channel in a G-protein-independent pathway.

ASIC1a is predominantly expressed in small-diameter DRG neurons^[23,51] and is less sensitive than ASIC3 with pH 0.5 for activation around 6.5^[29,30]. Mice lacking ASIC1a show normal mechanical sensitivity in cutaneous afferents but enhanced mechanically evoked firing rate in gastrointestinal afferents^[52,53]. In contrast to the ASIC3 role in secondary hyperalgesia, ASIC1a-deficient mice do not develop primary hyperalgesia induced by muscle inflammation, so ASIC1a and ASIC3 may play distinct roles in the development and maintenance of hyperalgesia, respectively^[43]. Downregulation of ASIC1a expression in spinal dorsal horn neurons by using selective inhibitor or antisense oligonucleotides reduces complete Freund's adjuvant (CFA)-induced thermal and mechanical hypersensitivity, which suggests that ASIC1a contributes to central sensitization in inflammatory pain^[54]. A recent study provides a new view for ASIC1a and ASIC3 roles in inflammatory pain in that acidosis may induce endocytosis and maturation of macrophages through ASIC1a and ASIC3^[55]. Mice lacking ASIC1a, ASIC2 and ASIC3 genes lost acid-induced transient currents, but their be-

havioral sensitivity to mechanical stimuli was increased, so ASICs indeed contribute cutaneous mechanosensation but in complex behavioral changes^[56].

PROTON-GATED ION CHANNELS: TRPV1

Transient receptor potential/vanilloid receptor subtype 1 (TRPV1/VR1) is a 6-transmembrane domain, non-selective cation channel and activated by vanilloid, heat, capsaicin, and proton^[57,58]. TRPV1 is predominantly expressed in small-diameter DRG neurons in rats and mice^[57]. Disruption of the TRPV1 gene in mice reduces responses of DRG neurons to acid and thermal stimuli and eliminates carrageenan-induced thermal hyperalgesia, so TRPV1 may be involved in acid-induced pain and inflammation-induced thermal hyperalgesia^[59,60]. However, surprisingly, blockage of the TRPV1 function in peripheral or spinal loci by selective antagonists inhibits mechanical hyperalgesia induced by CFA, capsaicin, or bone cancer^[61-64]. Although TRPV1 participates in both mechanical allodynia and thermal hyperalgesia induced by cutaneous inflammation, it does not participate in muscle inflammation^[65]. TRPV1 mediates the development of heat but not mechanical hypersensitivity after muscle inflammation^[66]. With peripheral inflammation, the mRNA TRPV1 expression is increased and the channel function enhanced in DRG neurons^[67-69]. Interestingly, DRG neurons with increased TRPV1 expression and function are mainly non-peptidergic rather than peptidergic neurons^[69]. Since most non-peptidergic neurons project to skin targets, TRPV1 would mainly participate in cutaneous inflammatory pain^[70,71]. Okun *et al.*^[72] suggested that CFA-induced ongoing pain is transient and depends on TRPV1-positive afferents but cannot be blocked by TRPV1 antagonism. TRPV1 may be responsive to noxious stimuli while nociceptors are sensitized (inflammation). Its function could be sensitized by inflammatory mediators such as BK^[73,74], chemokines (CCL3)^[75], 5-HT^[76], PGE₂^[77,78], proton^[79] or by protease-activated receptor 2^[80,81]. A recent study suggested that TRPV1 and TRPA1 are involved in the transition of acute to chronic pain in a chronic pancreatitis model^[82].

PROTON-SENSING G-PROTEIN-COUPLED RECEPTORS: OGR1 FAMILY

In 2003, Ludwig *et al.*^[83] found two GPCRs, ovarian cancer GPR 1 (OGR1) and G protein-coupled receptor 4 (GPR4), fully responsive to protons at pH 6.8 and stimulating inositol triphosphate and cAMP formation, respectively. Later, the 2 other family members, G2 accumulation (G2A) and T-cell death-associated gene 8 (TDAG8) were identified as proton receptors, with full activation at pH 6.4-6.8^[84-86]. OGR1, GPR4, and G2A were previously identified as receptors for sphingosylphosphorylcholine (SPC) or lysophosphatidylcholine (LPC), but the original publications have now been retracted^[87-89]. Whether OGR1, GPR4, and G2A are SPC or LPC receptors

remains unclear. In addition to responding to protons, TDAG8 also responds to psychosine^[85,89]. Although G2A was considered a proton-sensing receptor, Radu *et al*^[90] suggested that G2A is less likely to be a pH sensor because it does not generate a significant response after acid stimulation. G2A shows conservation of only 1 of 5 critical histidine residues that are involved in pH-sensing of OGR1, so G2A may be less sensitive to protons^[83]. Later, Obinata *et al*^[91] found that G2A can respond to oxidized free fatty acid (9-hydroxyoctadecadienoic acid, 9-HODE). Recent studies with gene-knockout techniques have revealed the absence of some but not all pH-induced cellular effects in OGR1-, TDAG8- or GPR4-deficient mice or cells, so OGR1 family members are indeed involved in proton sensing, and the pH-dependent activities could be highly cell-type- or signaling-pathway-specific^[90,92-94]. Interestingly, mice lacking G2A show some deficiencies in LPC- or acid-related cellular effects^[90,95-97]. Whether G2A is a proton, LPC or fatty acid receptor remains debated.

Proton-sensing GPCRs are widely expressed in non-neuronal and neuronal tissues^[98]. Approximately 75% to 82% of OGR1 family members are found in small-diameter DRG neurons responsible for nociception and 61% to 74% are present in isolectin B(4) (IB4)-positive neurons, so they may be involved in chronic pain^[79,98]. Indeed, one of the members, TDAG8, showed increased expression after CFA-induced inflammation, and its activation sensitizes TRPV1 function^[79]. TDAG8 is involved in CFA-induced inflammatory pain by modulating TRPV1 function. Later, knockdown of spinal TDAG8 expression was found to reduce bone cancer pain^[99]. Thus, TDAG8 could have pro-nociceptive roles in the peripheral and central nervous system. Although a recent study suggested that TDAG8 is a negative regulator in inflammation because of exacerbation of arthritis induced by anti-type II collagen antibody in TDAG8-deficient mice, whether TDAG8 has an anti-nociceptive role in inflammatory pain remains unclear^[100].

In endothelial cells, G2A expression blocks NF- κ B activation and chemokine expression, thus inhibiting macrophage accumulation, which suggests that G2A expression may have a protective role in preventing early events of inflammation^[96]. This situation could explain why G2A expression is downregulated in capsaicin- and CFA-induced inflammatory pain, so G2A could have an anti-nociceptive role in inflammatory pain^[79]. GPR4 is present in endothelial cells of blood vessels, and mice lacking GPR4 show vascular abnormalities, which suggests that GPR4 has a role in vascular growth and vascular stability^[93]. Vascular stability is important for leukocyte adhesion and function^[101]. GPR4 antagonism attenuates acidosis-induced inflammation and modulate a wide range of inflammatory genes in endothelial cells^[102].

SEROTONIN AND SEROTONIN RECEPTORS

In the periphery, serotonin (5-HT) released from plate-

lets, mast cells, and endothelial cells into the inflamed site is pro-inflammatory and pro-nociceptive, exciting nociceptive afferents and inducing hyperalgesia^[9,103-106]. In central loci, the descending pathway on serotonergic neurons from the rostral ventromedial medulla to the spinal cord has facilitatory or inhibitory effects on DRG neurons depending on the activation of 5-HT receptor subtypes^[107]. Seven subgroups of serotonin receptors (5-HT₁₋₇) have been identified, and some subtypes have more than one receptor (*e.g.*, 5-HT₁ has 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1D}, 5-HT_{1E}, and 5-HT_{1F}; and 5-HT₂ has 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C})^[108]. Although Sufka *et al*^[103] (1992) suggested that all of the 5-HT_{1A}, 5-HT_{2A}, and 5-HT₃ subtypes participate in 5-HT-induced pain, the presence of multiple 5-HT receptors on afferent nociceptors reflects distinct pain models or mechanisms.

Taiwo *et al*^[104] reported that only the 5-HT_{1A} agonist mimics the 5-HT effect to induce hyperalgesia and 5-HT_{1A} antagonists block mechanical hyperalgesia induced by 5-HT. Nevertheless, Kayser *et al*^[109] suggested that mice lacking 5-HT_{1A} show increased sensitivity to noxious heat but not mechanical pain stimuli. The other study of formalin testing also suggested that 5-HT_{1A} mediates antinociception^[110]. In addition to 5-HT_{1A}, the receptors 5-HT_{1B}, 5-HT_{1D} and 5-HT_{1F} also have anti-nociceptive effects in heat-evoked or formalin-induced nociceptive responses^[109,110]. Later, 5-HT_{2B/2C} but not 5-HT_{1A} was found to mediate 5-HT-induced mechanical hyperalgesia^[111]. Spinal and peripheral injection of a specific antagonist (RS127445) of 5-HT_{2B} reduced formalin-induced flinching behavior, which suggests that 5-HT_{2B} has a pro-nociceptive role in peripheral as well as spinal loci^[112]. However, Urtikova *et al*^[113] suggested that blockage of peripheral or spinal 5-HT_{2B} by a specific antagonist (RS127445) could enhance hyperalgesia induced by chronic constriction nerve injury. 5-HT_{2B} may have distinct roles in different pain models.

Ionotropic 5-HT₃ is directly responsible for inflammatory pain^[109,114,115]. Lack of the 5-HT₃ gene in mice or blocking with the 5-HT₃ antagonist granisetron elicited normal acute pain responses but reduced persistent pain responses^[109,115]. Giordano *et al*^[116] showed that 5-HT₃ contributes to chemical but not thermal and mechanical nociceptive pain. 5-HT_{2A} potentiates the effects of other inflammatory mediators^[117]. In the study by Tokunaga *et al*^[118], only the 5-HT_{2A} agonist but not 5-HT_{1A} and 5-HT_{3A} agonists mimicked 5-HT-induced thermal hyperalgesia, which was blocked by the 5-HT_{2A} antagonist ketanserin. However, Loyd *et al*^[119] suggested that both 5-HT-induced and 5-HT-enhanced capsaicin-evoked thermal hyperalgesia require 5-HT_{2A} and 5-HT₃. Likely, 5-HT_{2A} potentiates 5-HT₃-mediated nociceptive responses to thermal stimuli. Recent studies show that 5-HT_{2A} has a pronociceptive role in spinal nociceptive transmission and seems to be involved in both mechanical and thermal hyperalgesia in the spinal nerve ligation model^[120,121].

In addition, 5-HT₄ enhances the inflammatory pain signal^[122]. 5-HT₇ inhibits capsaicin-induced mechanical

sensitivity^[123]. Intrathecal injection of 5-HT_{2A}, 5-HT₃ and 5-HT₄ antagonists significantly reduced spinal cord stimulation-induced long-lasting pain in rat models, with no effect by administration of 5-HT_{1,6,7} antagonists^[124]. 5-HT₂ and 5-HT₇ are major receptors to potentiate TRPV1 function in inflammatory pain^[76].

PROSTAGLANDIN E2

Prostaglandin E2 (PGE₂), derived from an arachidonic acid by the cyclooxygenase (COX) pathway, is released from damaged cells and contributes to inflammatory pain^[125]. Non-steroidal anti-inflammatory drugs are the commonly used analgesics that reduce prostaglandin synthesis by inhibiting COX-1 and COX-2^[126]. Four subtypes of PGE₂ receptors (EP₁, EP₂, EP₃ and EP₄) belong to GPCRs^[125,127]. The roles of PGE₂ receptor subtypes in pain are undefined because of inconsistent results from studies involving gene targeting techniques, but are better resolved in combined studies with pharmacological approaches^[126]. PGE₂-induced thermal hyperalgesia is mediated by EP₁ predominantly through a PKC-dependent pathway and is due to potentiation or sensitization of TRPV1^[77]. Wang and colleagues showed that PGE₂-induced pain is mediated by EP₃ through PKA and Epac/PKC pathways to sensitize purinergic P2X₃ receptors^[78,128]. Several lines of evidence also support the roles of PGE₂ in modulating pain transduction. PGE₂ potentiates the TRPV1 function in response to capsaicin^[78]. Repeated administration of PGE₂ sensitizes T-type calcium channels, thus resulting in mechanical hyperalgesia^[129]. PGE₂ potentiates the voltage-gated tetrodotoxin-resistant sodium channels (Nav1.5, Nav1.8 and Nav1.9) by a cAMP-PKA signaling pathway^[130,131].

TRANSITION FROM ACUTE TO CHRONIC PAIN

The possible mechanisms of chronic inflammatory pain could be that continuous sensitization induced by inflammatory mediators in primary afferent nociceptors results in persistent and long-lasting pain or neuroplastic changes in primary afferent nociceptors after initiating insults lead to enhanced and prolonged sensitization of nociceptors even with low-level exposure of pro-nociceptive inflammatory mediators. The mechanisms of chronic pain and the regulation of the transition from short-term to long-lasting pain have become clearer from studies with the PGE₂ priming model.

Administration of PGE₂ in rat induces short-term hyperalgesia that depends on PKA activity^[132]. With carageenan pre-injection, rats display long-lasting hyperalgesia induced by PGE₂, and the prolonged effect can be inhibited by PKC ϵ blocker or attenuated by antisense oligonucleotides for PKC ϵ ^[133,134]. Therefore, PKC ϵ may be necessary to maintain hyperalgesic priming. Indeed, a highly selective PKC agonist can induce hyperalgesic priming in rat^[134]. In contrast, the study by Ferrari *et*

al^[135] proposed that a transient decrease in GRK2 levels leads to increased nociceptor response to inflammatory mediators, and the reduced GRK2 levels are PKA- but not PKC-dependent. Ferrari *et al*^[136] later proposed that the prolongation of PGE₂-induced hyperalgesia is mediated by an autocrine mechanism. PGE₂ activates EP receptors followed by cAMP production, which in turn activates PKA and induces hyperalgesia. The increase in intracellular cAMP level triggers the transporter to transport cAMP outside the cell. The extracellular cAMP is metabolized to AMP and adenosine, thus activating the Gi-coupled A₁ adenosine receptor. The Gi pathway stimulates PKC ϵ , which is responsible for the late phase of PGE₂-induced hyperalgesia, although evidence has shown that after injury, the inflammatory mediators may release and reach the effective concentration in a different time course. Each mediator activates its own receptor subtypes, thus contributing to the development of hyperalgesia. However, which receptor is the major receptor causing the acute to chronic pain remains unclear.

ESTABLISHMENT AND MAINTENANCE OF CHRONIC PAIN: THE ROLE OF AN EXCITATORY AMINO ACID IN CENTRAL SENSITIZATION

The establishment and maintenance of chronic pain is not simply a reflection of peripheral inputs or abnormality but is also a dynamic reflection of central neuronal plasticity. Once the central sensitization occurs, painful sensations are generated even in the absence of the noxious stimulus^[137]. Several lines of evidence implicate the contribution of excitatory amino acids in neuroplasticity and central sensitization in the spinal cord. Noxious stimulation or peripheral inflammation causes the release of an excitatory amino acid, glutamate, in the spinal dorsal horn^[138,139]. Dorsal horn neurons that are sensitized with peripheral inflammation show increased responsiveness to the iontophoretic application of the excitatory amino acid^[139,140], and such responsiveness or sensitization is reduced after the administration of glutamate receptor antagonists^[141,142].

Glutamate receptors include ionotropic amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), N-methyl-D-aspartate (NMDA), kainate receptors and metabotropic G-protein-coupled glutamate receptors (mGluRs). The contribution of ionotropic glutamate receptors to the central sensitization are considered the ability of AMPA and NMDA receptor antagonists to reduce the responsiveness of dorsal horn neurons and in producing analgesic effects^[142]. Intrathecal injection of NMDA leads to hyperalgesia, which can be reversed by application of an NMDA antagonist^[143]. The NMDA antagonist MK-801 reduces the hyperalgesia that develops in rats with adjuvant-induced inflammation^[144] or reduces the inflammation-induced expansion of the receptive field of spinal nociceptive neurons^[145].

Peripheral inflammation elevates levels of phosphorylated NMDA receptors in the spinal dorsal horn^[146,147]. The sustained release of the neuropeptides (such as substance P and CGRP) and glutamate causes PKC activation and Ca^{2+} influxes through NMDA receptors. With Ca^{2+} influx, several intracellular signal pathways, including the phospholipase C-PKC pathway, phosphatidylinositol-3-kinase (PI3K) pathway, and mitogen-activated protein kinase (MAPK) pathway, are activated. Activated intracellular signaling pathways result in phosphorylation of spinal NMDA receptors, enhancing Ca^{2+} currents at NMDA receptors. Activated intracellular signaling pathways also phosphorylate AMPA receptors, thus increasing the density of AMPA receptors on the membrane^[148]. These mechanisms create a positive feedback loop for glutamate transmission and alter the neuronal plasticity in the dorsal horn. In the formalin-induced inflammatory pain model, intrathecal injection of the MEK inhibitor PD98059 can reduce the second phase of the licking/lifting behavior and attenuate extracellular signal-regulated kinase activity, so some intracellular signaling pathways may also be involved in central sensitization^[149].

CONCLUSION

At the inflamed site of the tissue, endogenous mediators (5-HT, PGE_2 , BK, and proton) are released from damaged cells and accumulate. Nociceptors innervating the skin, muscle and organs detect the noxious stimuli and express one or more cell-surface receptors to respond to these inflammatory mediators. The mediators can directly or indirectly alter the sensitivity of the receptors on nociceptors. ASIC3, ASIC1a and TRPV1 seem to be important transducer receptors contributing to hyperalgesia induced by inflammation. ASIC1a participates in primary mechanical hyperalgesia induced by muscle inflammation, but ASIC3 may have a predominant role in secondary mechanical hyperalgesia. TRPV1 could be responsible for mechanical and thermal hyperalgesia induced by cutaneous inflammation. Inflammatory mediators such as 5-HT, PGE_2 , BK, and proton sensitize TRPV1 or ASIC3 to prolong the hyperalgesia. PGE_2 acts on EP_1 to sensitize TRPV1 or on EP_3 to sensitize P2X_3 . Proton and BK sensitize TRPV1 through TDAG8 and B_2 , respectively. 5-HT potentiates TRPV1 function, possibly through 5-HT₂ and 5-HT₇. Although each mediator receptor has its own dominant second-messenger signaling cascade, each could also be coupled in part to other second-messenger pathways. For short-term hyperalgesia, the cAMP-PKA pathway is dominant, but prolonged hyperalgesia is regulated by PKC ϵ -dependent or -independent pathway.

The signal of a stimulus is triggered by a peripheral nociceptor, followed by conduction to central neurons. In acute pain, the signal is mediated by glutamate acting on AMPA and kainate subtypes of ionotropic glutamate receptors of postsynaptic neurons and generating the excitatory postsynaptic potential. If the signal is generated by intense or persistent noxious stimuli, the depolarization of the postsynaptic neurons will activate NMDA re-

ceptors. NMDA receptor activation induces Ca^{2+} influx, which activates intracellular signaling pathways to further enhance Ca^{2+} influx through NMDA receptors. NMDA receptors can also be modulated by GPCRs such as NK1, EP or mGlu receptors that are also expressed on the superficial dorsal horn of nociceptor terminals^[150]. All these NMDA-receptor-mediated mechanisms contribute to central sensitization, which is important for establishing and maintaining chronic pain^[151].

REFERENCES

- 1 Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. *Nat Rev Neurosci* 2005; **6**: 521-532 [PMID: 15995723 DOI: 10.1038/nrn1700]
- 2 Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. *Cell* 2009; **139**: 267-284 [PMID: 19837031 DOI: 10.1016/j.cell.2009.09.028]
- 3 Julius D, Basbaum AI. Molecular mechanisms of nociception. *Nature* 2001; **413**: 203-210 [PMID: 11557989 DOI: 10.1038/35093019]
- 4 Scholz J, Woolf CJ. Can we conquer pain? *Nat Neurosci* 2002; **5** Suppl: 1062-1067 [PMID: 12403987 DOI: 10.1038/nn942]
- 5 Beck PW, Handwerker HO. Bradykinin and serotonin effects on various types of cutaneous nerve fibers. *Pflugers Arch* 1974; **347**: 209-222 [PMID: 4857072 DOI: 10.1007/BF00592598]
- 6 Schaible HG, Schmidt RF. Excitation and sensitization of fine articular afferents from cat's knee joint by prostaglandin E_2 . *J Physiol* 1988; **403**: 91-104 [PMID: 3253427]
- 7 Steen KH, Reeh PW, Anton F, Handwerker HO. Protons selectively induce lasting excitation and sensitization to mechanical stimulation of nociceptors in rat skin, in vitro. *J Neurosci* 1992; **12**: 86-95 [PMID: 1309578]
- 8 Steen KH, Reeh PW, Kreysel HW. Topical acetylsalicylic, salicylic acid and indomethacin suppress pain from experimental tissue acidosis in human skin. *Pain* 1995; **62**: 339-347 [PMID: 8657434 DOI: 10.1016/0304-3959(95)00011-G]
- 9 Kessler W, Kirchhoff C, Reeh PW, Handwerker HO. Excitation of cutaneous afferent nerve endings in vitro by a combination of inflammatory mediators and conditioning effect of substance P. *Exp Brain Res* 1992; **91**: 467-476 [PMID: 1282891 DOI: 10.1007/BF00227842]
- 10 Steen KH, Steen AE, Kreysel HW, Reeh PW. Inflammatory mediators potentiate pain induced by experimental tissue acidosis. *Pain* 1996; **66**: 163-170 [PMID: 8880837 DOI: 10.1016/0304-3959(96)03034-5]
- 11 Dubé GR, Elagoz A, Mangat H. Acid sensing ion channels and acid nociception. *Curr Pharm Des* 2009; **15**: 1750-1766 [PMID: 19442188 DOI: 10.2174/138161209788186263]
- 12 Woo YC, Park SS, Subieta AR, Brennan TJ. Changes in tissue pH and temperature after incision indicate acidosis may contribute to postoperative pain. *Anesthesiology* 2004; **101**: 468-475 [PMID: 15277931 DOI: 10.1097/0000542-200408000-00029]
- 13 Jacobus WE, Taylor GJ, Hollis DP, Nunnally RL. Phosphorus nuclear magnetic resonance of perfused working rat hearts. *Nature* 1977; **265**: 756-758 [PMID: 16217 DOI: 10.1038/265756a0]
- 14 Pan HL, Longhurst JC, Eisenach JC, Chen SR. Role of protons in activation of cardiac sympathetic C-fibre afferents during ischaemia in cats. *J Physiol* 1999; **518** (Pt 3): 857-866 [PMID: 10420020 DOI: 10.1111/j.1469-7793.1999.0857p.x]
- 15 Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO_2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. *Nat Med* 1997; **3**: 177-182 [PMID: 9018236 DOI: 10.1038/nm0297-177]
- 16 Steen KH, Reeh PW. Sustained graded pain and hyperalgesia from harmless experimental tissue acidosis in human skin. *Neurosci Lett* 1993; **154**: 113-116 [PMID: 8361622 DOI: 10.1016/0304-3959(93)90011-G]

- 10.1016/0304-3940(93)90184-M]
- 17 **Steen KH**, Issberner U, Reeh PW. Pain due to experimental acidosis in human skin: evidence for non-adapting nociceptor excitation. *Neurosci Lett* 1995; **199**: 29-32 [PMID: 8584219 DOI: 10.1016/0304-3940(95)12002-L]
 - 18 **Steen KH**, Steen AE, Reeh PW. A dominant role of acid pH in inflammatory excitation and sensitization of nociceptors in rat skin, in vitro. *J Neurosci* 1995; **15**: 3982-3989 [PMID: 7751959]
 - 19 **Bevan S**, Yeats J. Protons activate a cation conductance in a sub-population of rat dorsal root ganglion neurones. *J Physiol* 1991; **433**: 145-161 [PMID: 1726795]
 - 20 **Kress M**, Reeh PW, Vyklicky L. An interaction of inflammatory mediators and protons in small diameter dorsal root ganglion neurons of the rat. *Neurosci Lett* 1997; **224**: 37-40 [PMID: 9132685 DOI: 10.1016/S0304-3940(97)13450-4]
 - 21 **Krishtal OA**, Pidoplichko VI. A receptor for protons in the nerve cell membrane. *Neuroscience* 1980; **5**: 2325-2327 [PMID: 6970348 DOI: 10.1016/0306-4522(80)90149-9]
 - 22 **Waldmann R**, Champigny G, Bassilana F, Heurteaux C, Lazdunski M. A proton-gated cation channel involved in acid-sensing. *Nature* 1997; **386**: 173-177 [PMID: 9062189 DOI: 10.1038/386173a0]
 - 23 **Chen CC**, England S, Akopian AN, Wood JN. A sensory neuron-specific, proton-gated ion channel. *Proc Natl Acad Sci USA* 1998; **95**: 10240-10245 [PMID: 9707631 DOI: 10.1073/pnas.95.17.10240]
 - 24 **Waldmann R**, Bassilana F, de Weille J, Champigny G, Heurteaux C, Lazdunski M. Molecular cloning of a non-inactivating proton-gated Na⁺ channel specific for sensory neurons. *J Biol Chem* 1997; **272**: 20975-20978 [PMID: 9261094 DOI: 10.1074/jbc.272.34.20975]
 - 25 **Bassilana F**, Champigny G, Waldmann R, de Weille JR, Heurteaux C, Lazdunski M. The acid-sensitive ionic channel subunit ASIC and the mammalian degenerin MDEG form a heteromultimeric H⁺-gated Na⁺ channel with novel properties. *J Biol Chem* 1997; **272**: 28819-28822 [PMID: 9360943 DOI: 10.1074/jbc.272.46.28819]
 - 26 **Deval E**, Gasull X, Noël J, Salinas M, Baron A, Diochot S, Lingueglia E. Acid-sensing ion channels (ASICs): pharmacology and implication in pain. *Pharmacol Ther* 2010; **128**: 549-558 [PMID: 20807551 DOI: 10.1016/j.pharmthera.2010.08.006]
 - 27 **Wemmie JA**, Taugher RJ, Kreple CJ. Acid-sensing ion channels in pain and disease. *Nat Rev Neurosci* 2013; **14**: 461-471 [PMID: 23783197 DOI: 10.1038/nrn3529]
 - 28 **Wiemuth D**, Sahin H, Falkenburger BH, Lefèvre CM, Wasmuth HE, Gründer S. ASIC--a bile acid-sensitive ion channel highly expressed in bile ducts. *FASEB J* 2012; **26**: 4122-4130 [PMID: 22735174 DOI: 10.1096/fj.12-207043]
 - 29 **Sutherland SP**, Benson CJ, Adelman JP, McCleskey EW. Acid-sensing ion channel 3 matches the acid-gated current in cardiac ischemia-sensing neurons. *Proc Natl Acad Sci USA* 2001; **98**: 711-716 [PMID: 11120882 DOI: 10.1073/pnas.98.2.711]
 - 30 **Yagi J**, Wenk HN, Naves LA, McCleskey EW. Sustained currents through ASIC3 ion channels at the modest pH changes that occur during myocardial ischemia. *Circ Res* 2006; **99**: 501-509 [PMID: 16873722 DOI: 10.1161/01.RES.0000238388.79295.4c]
 - 31 **Wu WL**, Cheng CF, Sun WH, Wong CW, Chen CC. Targeting ASIC3 for pain, anxiety, and insulin resistance. *Pharmacol Ther* 2012; **134**: 127-138 [PMID: 22233754 DOI: 10.1016/j.pharmthera.2011.12.009]
 - 32 **Voilley N**, de Weille J, Mamet J, Lazdunski M. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. *J Neurosci* 2001; **21**: 8026-8033 [PMID: 11588175]
 - 33 **Mamet J**, Baron A, Lazdunski M, Voilley N. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. *J Neurosci* 2002; **22**: 10662-10670 [PMID: 12486159]
 - 34 **Deval E**, Noël J, Lay N, Alloui A, Diochot S, Friend V, Jodar M, Lazdunski M, Lingueglia E. ASIC3, a sensor of acidic and primary inflammatory pain. *EMBO J* 2008; **27**: 3047-3055 [PMID: 18923424 DOI: 10.1038/emboj.2008.213]
 - 35 **Allen NJ**, Attwell D. Modulation of ASIC channels in rat cerebellar Purkinje neurons by ischaemia-related signals. *J Physiol* 2002; **543**: 521-529 [PMID: 12205186 DOI: 10.1113/jphysiol.2002.020297]
 - 36 **Smith ES**, Cadiou H, McNaughton PA. Arachidonic acid potentiates acid-sensing ion channels in rat sensory neurons by a direct action. *Neuroscience* 2007; **145**: 686-698 [PMID: 17258862 DOI: 10.1016/j.neuroscience.2006.12.024]
 - 37 **Cadiou H**, Studer M, Jones NG, Smith ES, Ballard A, McMahon SB, McNaughton PA. Modulation of acid-sensing ion channel activity by nitric oxide. *J Neurosci* 2007; **27**: 13251-13260 [PMID: 18045919 DOI: 10.1523/JNEUROSCI.2135-07.2007]
 - 38 **Wang X**, Li WG, Yu Y, Xiao X, Cheng J, Zeng WZ, Peng Z, Xi Zhu M, Xu TL. Serotonin facilitates peripheral pain sensitivity in a manner that depends on the nonproton ligand sensing domain of ASIC3 channel. *J Neurosci* 2013; **33**: 4265-4279 [PMID: 23467344 DOI: 10.1523/JNEUROSCI.3376-12.2013]
 - 39 **Price MP**, McIlwrath SL, Xie J, Cheng C, Qiao J, Tarr DE, Sluka KA, Brennan TJ, Lewin GR, Welsh MJ. The DRASIC cation channel contributes to the detection of cutaneous touch and acid stimuli in mice. *Neuron* 2001; **32**: 1071-1083 [PMID: 11754838 DOI: 10.1016/S0896-6273(01)00547-5]
 - 40 **Chen CC**, Wong CW. Neurosensory mechanotransduction through acid-sensing ion channels. *J Cell Mol Med* 2013; **17**: 337-349 [PMID: 23490035 DOI: 10.1111/jcmm.12025]
 - 41 **Chen CC**, Zimmer A, Sun WH, Hall J, Brownstein MJ, Zimmer A. A role for ASIC3 in the modulation of high-intensity pain stimuli. *Proc Natl Acad Sci USA* 2002; **99**: 8992-8997 [PMID: 12060708 DOI: 10.1073/pnas.122245999]
 - 42 **Ikeuchi M**, Kolker SJ, Burnes LA, Walder RY, Sluka KA. Role of ASIC3 in the primary and secondary hyperalgesia produced by joint inflammation in mice. *Pain* 2008; **137**: 662-669 [PMID: 18343037 DOI: 10.1016/j.pain.2008.01.020]
 - 43 **Walder RY**, Rasmussen LA, Rainier JD, Light AR, Wemmie JA, Sluka KA. ASIC1 and ASIC3 play different roles in the development of Hyperalgesia after inflammatory muscle injury. *J Pain* 2010; **11**: 210-218 [PMID: 20015700 DOI: 10.1016/j.pain.2009.07.004]
 - 44 **Deval E**, Noël J, Gasull X, Delaunay A, Alloui A, Friend V, Eschalier A, Lazdunski M, Lingueglia E. Acid-sensing ion channels in postoperative pain. *J Neurosci* 2011; **31**: 6059-6066 [PMID: 21508231 DOI: 10.1523/JNEUROSCI.5266-10.2011]
 - 45 **Molliver DC**, Immke DC, Fierro L, Paré M, Rice FL, McCleskey EW. ASIC3, an acid-sensing ion channel, is expressed in metaboreceptive sensory neurons. *Mol Pain* 2005; **1**: 35 [PMID: 16305749 DOI: 10.1186/1744-8069-1-35]
 - 46 **Sluka KA**, Price MP, Breese NM, Stucky CL, Wemmie JA, Welsh MJ. Chronic hyperalgesia induced by repeated acid injections in muscle is abolished by the loss of ASIC3, but not ASIC1. *Pain* 2003; **106**: 229-239 [PMID: 14659506 DOI: 10.1016/S0304-3959(03)00269-0]
 - 47 **Sluka KA**, Radhakrishnan R, Benson CJ, Eshcol JO, Price MP, Babinski K, Audette KM, Yeomans DC, Wilson SP. ASIC3 in muscle mediates mechanical, but not heat, hyperalgesia associated with muscle inflammation. *Pain* 2007; **129**: 102-112 [PMID: 17134831 DOI: 10.1016/j.pain.2006.09.038]
 - 48 **Yen YT**, Tu PH, Chen CJ, Lin YW, Hsieh ST, Chen CC. Role of acid-sensing ion channel 3 in sub-acute-phase inflammation. *Mol Pain* 2009; **5**: 1 [PMID: 19126241 DOI: 10.1186/1744-8069-5-1]
 - 49 **Walder RY**, Gautam M, Wilson SP, Benson CJ, Sluka KA. Selective targeting of ASIC3 using artificial miRNAs inhibits primary and secondary hyperalgesia after muscle inflam-

- mation. *Pain* 2011; **152**: 2348-2356 [PMID: 21843914 DOI: 10.1016/j.pain.2011.06.027]
- 50 **Lin CC**, Chen WN, Chen CJ, Lin YW, Zimmer A, Chen CC. An antinociceptive role for substance P in acid-induced chronic muscle pain. *Proc Natl Acad Sci USA* 2012; **109**: E76-E83 [PMID: 22084095 DOI: 10.1073/pnas.1108903108]
 - 51 **Alvarez de la Rosa D**, Zhang P, Shao D, White F, Canessa CM. Functional implications of the localization and activity of acid-sensitive channels in rat peripheral nervous system. *Proc Natl Acad Sci USA* 2002; **99**: 2326-2331 [PMID: 11842212 DOI: 10.1073/pnas.042688199]
 - 52 **Page AJ**, Brierley SM, Martin CM, Price MP, Symonds E, Butler R, Wemmie JA, Blackshaw LA. Different contributions of ASIC channels 1a, 2, and 3 in gastrointestinal mechanosensory function. *Gut* 2005; **54**: 1408-1415 [PMID: 15987792 DOI: 10.1136/gut.2005.071084]
 - 53 **Page AJ**, Brierley SM, Martin CM, Martinez-Salgado C, Wemmie JA, Brennan TJ, Symonds E, Omari T, Lewin GR, Welsh MJ, Blackshaw LA. The ion channel ASIC1 contributes to visceral but not cutaneous mechanoreceptor function. *Gastroenterology* 2004; **127**: 1739-1747 [PMID: 15578512 DOI: 10.1053/j.gastro.2004.08.061]
 - 54 **Duan B**, Wu LJ, Yu YQ, Ding Y, Jing L, Xu L, Chen J, Xu TL. Upregulation of acid-sensing ion channel ASIC1a in spinal dorsal horn neurons contributes to inflammatory pain hypersensitivity. *J Neurosci* 2007; **27**: 11139-11148 [PMID: 17928456 DOI: 10.1523/JNEUROSCI.3364-07.2007]
 - 55 **Kong X**, Tang X, Du W, Tong J, Yan Y, Zheng F, Fang M, Gong F, Tan Z. Extracellular acidosis modulates the endocytosis and maturation of macrophages. *Cell Immunol* 2013; **281**: 44-50 [PMID: 23435349 DOI: 10.1016/j.cellimm.2012.12.009]
 - 56 **Kang S**, Jang JH, Price MP, Gautam M, Benson CJ, Gong H, Welsh MJ, Brennan TJ. Simultaneous disruption of mouse ASIC1a, ASIC2 and ASIC3 genes enhances cutaneous mechanosensitivity. *PLoS One* 2012; **7**: e35225 [PMID: 22506072 DOI: 10.1371/journal.pone.0035225]
 - 57 **Caterina MJ**, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* 1997; **389**: 816-824 [PMID: 9349813 DOI: 10.1038/39807]
 - 58 **Tominaga M**, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. *Neuron* 1998; **21**: 531-543 [PMID: 9768840 DOI: 10.1016/S0896-6273(00)80564-4]
 - 59 **Caterina MJ**, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeit K, Koltzenburg M, Basbaum AI, Julius D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. *Science* 2000; **288**: 306-313 [PMID: 10764638 DOI: 10.1126/science.288.5464.306]
 - 60 **Davis JB**, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. *Nature* 2000; **405**: 183-187 [PMID: 10821274 DOI: 10.1038/35012076]
 - 61 **Gavva NR**, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, Wang J, Zhu D, Vanderah TW, Porreca F, Doherty EM, Norman MH, Wild KD, Bannon AW, Louis JC, Treanor JJ. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. *J Pharmacol Exp Ther* 2005; **313**: 474-484 [PMID: 15615864 DOI: 10.1124/jpet.104.079855]
 - 62 **Ghilardi JR**, Röhrich H, Lindsay TH, Sevcik MA, Schwei MJ, Kubota K, Halvorson KG, Poblete J, Chaplan SR, Dubin AE, Carruthers NI, Swanson D, Kuskowski M, Flores CM, Julius D, Mantyh PW. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. *J Neurosci* 2005; **25**: 3126-3131 [PMID: 15788769 DOI: 10.1523/JNEUROSCI.3815-04.2005]
 - 63 **Cui M**, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, Chandran P, Gomtsyan A, Brown B, Bayburt EK, Marsh K, Bianchi B, McDonald H, Niforatos W, Neelands TR, Moreland RB, Decker MW, Lee CH, Sullivan JP, Faltynek CR. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. *J Neurosci* 2006; **26**: 9385-9393 [PMID: 16971522 DOI: 10.1523/JNEUROSCI.1246-06.2006]
 - 64 **Kim MS**, Ryu H, Kang DW, Cho SH, Seo S, Park YS, Kim MY, Kwak EJ, Kim YS, Bhondwe RS, Kim HS, Park SG, Son K, Choi S, DeAndrea-Lazarus IA, Pearce LV, Blumberg PM, Frank R, Bahrenberg G, Stockhausen H, Kögel BY, Schiene K, Christoph T, Lee J. 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-region. *J Med Chem* 2012; **55**: 8392-8408 [PMID: 22957803 DOI: 10.1021/jm300780p]
 - 65 **Yu L**, Yang F, Luo H, Liu FY, Han JS, Xing GG, Wan Y. The role of TRPV1 in different subtypes of dorsal root ganglion neurons in rat chronic inflammatory nociception induced by complete Freund's adjuvant. *Mol Pain* 2008; **4**: 61 [PMID: 19055783 DOI: 10.1186/1744-8069-4-61]
 - 66 **Walder RY**, Radhakrishnan R, Loo L, Rasmussen LA, Mohapatra DP, Wilson SP, Sluka KA. TRPV1 is important for mechanical and heat sensitivity in uninjured animals and development of heat hypersensitivity after muscle inflammation. *Pain* 2012; **153**: 1664-1672 [PMID: 22694790 DOI: 10.1016/j.pain.2012.04.034]
 - 67 **Carlton SM**, Coggeshall RE. Peripheral capsaicin receptors increase in the inflamed rat hindpaw: a possible mechanism for peripheral sensitization. *Neurosci Lett* 2001; **310**: 53-56 [PMID: 11524156 DOI: 10.1016/S0304-3940(01)02093-6]
 - 68 **Amaya F**, Oh-hashii K, Naruse Y, Iijima N, Ueda M, Shimotsato G, Tominaga M, Tanaka Y, Tanaka M. Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons. *Brain Res* 2003; **963**: 190-196 [PMID: 12560124 DOI: 10.1016/S0006-8993(02)03972-0]
 - 69 **Breese NM**, George AC, Pauers LE, Stucky CL. Peripheral inflammation selectively increases TRPV1 function in IB4-positive sensory neurons from adult mouse. *Pain* 2005; **115**: 37-49 [PMID: 15836968 DOI: 10.1016/j.pain.2005.02.010]
 - 70 **Lu J**, Zhou XF, Rush RA. Small primary sensory neurons innervating epidermis and viscera display differential phenotype in the adult rat. *Neurosci Res* 2001; **41**: 355-363 [PMID: 11755222 DOI: 10.1016/S0168-0102(01)00293-0]
 - 71 **Plenderleith MB**, Snow PJ. The plant lectin Bandeiraea simplicifolia I-B4 identifies a subpopulation of small diameter primary sensory neurones which innervate the skin in the rat. *Neurosci Lett* 1993; **159**: 17-20 [PMID: 8264961 DOI: 10.1016/0304-3940(93)90787-L]
 - 72 **Okun A**, DeFelice M, Eyde N, Ren J, Mercado R, King T, Porreca F. Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents. *Mol Pain* 2011; **7**: 4 [PMID: 21219650 DOI: 10.1186/1744-8069-7-7]
 - 73 **Chuang HH**, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI, Chao MV, Julius D. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. *Nature* 2001; **411**: 957-962 [PMID: 11418861 DOI: 10.1038/35082088]
 - 74 **Premkumar LS**, Ahern GP. Induction of vanilloid receptor channel activity by protein kinase C. *Nature* 2000; **408**: 985-990 [PMID: 11140687 DOI: 10.1038/35050121]
 - 75 **Zhang N**, Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Caterina M, Oppenheim JJ. A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. *Proc Natl Acad Sci USA* 2005; **102**: 4536-4541 [PMID: 15788769 DOI: 10.1523/JNEUROSCI.3815-04.2005]

- 15764707 DOI: 10.1073/pnas.0406030102]
- 76 **Ohta T**, Ikemi Y, Murakami M, Imagawa T, Otsuguro K, Ito S. Potentiation of transient receptor potential V1 functions by the activation of metabotropic 5-HT receptors in rat primary sensory neurons. *J Physiol* 2006; **576**: 809-822 [PMID: 16901936 DOI: 10.1113/jphysiol.2006.112250]
 - 77 **Moriyama T**, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, Tominaga T, Narumiya S, Tominaga M. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. *Mol Pain* 2005; **1**: 3 [PMID: 15813989 DOI: 10.1186/1744-8069-1-3]
 - 78 **Wang C**, Gu Y, Li GW, Huang LY. A critical role of the cAMP sensor Epac in switching protein kinase signalling in prostaglandin E2-induced potentiation of P2X3 receptor currents in inflamed rats. *J Physiol* 2007; **584**: 191-203 [PMID: 17702820 DOI: 10.1113/jphysiol.2007.135616]
 - 79 **Chen YJ**, Huang CW, Lin CS, Chang WH, Sun WH. Expression and function of proton-sensing G-protein-coupled receptors in inflammatory pain. *Mol Pain* 2009; **5**: 39 [PMID: 19602228 DOI: 10.1186/1744-8069-5-39]
 - 80 **Amadesi S**, Nie J, Vergnolle N, Cottrell GS, Grady EF, Trevisani M, Manni C, Geppetti P, McRoberts JA, Ennes H, Davis JB, Mayer EA, Bunnett NW. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. *J Neurosci* 2004; **24**: 4300-4312 [PMID: 15128844 DOI: 10.1523/JNEUROSCI.5679-03.2004]
 - 81 **Amadesi S**, Cottrell GS, Divino L, Chapman K, Grady EF, Bautista F, Karanjia R, Barajas-Lopez C, Vanner S, Vergnolle N, Bunnett NW. Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice. *J Physiol* 2006; **575**: 555-571 [PMID: 16793902 DOI: 10.1113/jphysiol.2006.111534]
 - 82 **Schwartz ES**, La JH, Scheff NN, Davis BM, Albers KM, Gebhart GF. TRPV1 and TRPA1 antagonists prevent the transition of acute to chronic inflammation and pain in chronic pancreatitis. *J Neurosci* 2013; **33**: 5603-5611 [PMID: 23536075 DOI: 10.1523/JNEUROSCI.1806-12.2013]
 - 83 **Ludwig MG**, Vanek M, Guerini D, Gasser JA, Jones CE, Junker U, Hofstetter H, Wolf RM, Seuwen K. Proton-sensing G-protein-coupled receptors. *Nature* 2003; **425**: 93-98 [PMID: 12955148 DOI: 10.1038/nature01905]
 - 84 **Murakami N**, Yokomizo T, Okuno T, Shimizu T. G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. *J Biol Chem* 2004; **279**: 42484-42491 [PMID: 15280385 DOI: 10.1074/jbc.M406561200]
 - 85 **Wang JQ**, Kon J, Mogi C, Tobo M, Damirin A, Sato K, Komachi M, Malchinkhuu E, Murata N, Kimura T, Kuwabara A, Wakamatsu K, Koizumi H, Uede T, Tsujimoto G, Kurose H, Sato T, Harada A, Misawa N, Tomura H, Okajima F. TDAG8 is a proton-sensing and psychosine-sensitive G-protein-coupled receptor. *J Biol Chem* 2004; **279**: 45626-45633 [PMID: 15326175 DOI: 10.1074/jbc.M406966200]
 - 86 **Ishii S**, Kihara Y, Shimizu T. Identification of T cell death-associated gene 8 (TDAG8) as a novel acid sensing G-protein-coupled receptor. *J Biol Chem* 2005; **280**: 9083-9087 [PMID: 15618224 DOI: 10.1074/jbc.M407832200]
 - 87 **Kabarowski JH**, Zhu K, Le LQ, Witte ON, Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. *Science* 2001; **293**: 702-705 [PMID: 11474113 DOI: 10.1126/science.1061781]
 - 88 **Xu Y**, Zhu K, Hong G, Wu W, Baudhuin LM, Xiao Y, Dameron DS. Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. *Nat Cell Biol* 2000; **2**: 261-267 [PMID: 10806476 DOI: 10.1038/35010529]
 - 89 **Zhu K**, Baudhuin LM, Hong G, Williams FS, Cristina KL, Kabarowski JH, Witte ON, Xu Y. Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. *J Biol Chem* 2001; **276**: 41325-41335 [PMID: 11535583 DOI: 10.1074/jbc.M008057200]
 - 90 **Radu CG**, Nijagal A, McLaughlin J, Wang L, Witte ON. Differential proton sensitivity of related G protein-coupled receptors T cell death-associated gene 8 and G2A expressed in immune cells. *Proc Natl Acad Sci USA* 2005; **102**: 1632-1637 [PMID: 15665078 DOI: 10.1073/pnas.0409415102]
 - 91 **Obinata H**, Hattori T, Nakane S, Tatei K, Izumi T. Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. *J Biol Chem* 2005; **280**: 40676-40683 [PMID: 16236715 DOI: 10.1074/jbc.M507787200]
 - 92 **Radu CG**, Cheng D, Nijagal A, Riedinger M, McLaughlin J, Yang LV, Johnson J, Witte ON. Normal immune development and glucocorticoid-induced thymocyte apoptosis in mice deficient for the T-cell death-associated gene 8 receptor. *Mol Cell Biol* 2006; **26**: 668-677 [PMID: 16382156 DOI: 10.1128/MCB.26.2.668-677.2006]
 - 93 **Yang LV**, Radu CG, Roy M, Lee S, McLaughlin J, Teitell MA, Iruela-Arispe ML, Witte ON. Vascular abnormalities in mice deficient for the G protein-coupled receptor GPR4 that functions as a pH sensor. *Mol Cell Biol* 2007; **27**: 1334-1347 [PMID: 17145776 DOI: 10.1128/MCB.01909-06]
 - 94 **Li H**, Wang D, Singh LS, Berk M, Tan H, Zhao Z, Steinmetz R, Kirmani K, Wei G, Xu Y. Abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer G protein-coupled receptor 1. *PLoS One* 2009; **4**: e5705 [PMID: 19479052 DOI: 10.1371/journal.pone.0005705]
 - 95 **Le LQ**, Kabarowski JH, Weng Z, Satterthwaite AB, Harvill ET, Jensen ER, Miller JF, Witte ON. Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. *Immunity* 2001; **14**: 561-571 [PMID: 11371358 DOI: 10.1016/S1074-7613(01)00145-5]
 - 96 **Bolick DT**, Whetzel AM, Skaffen M, Deem TL, Lee J, Hedrick CC. Absence of the G protein-coupled receptor G2A in mice promotes monocyte/endothelial interactions in aorta. *Circ Res* 2007; **100**: 572-580 [PMID: 17255525 DOI: 10.1161/01.RES.0000258877.57836.d2]
 - 97 **Yan JJ**, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, Kim YH, Song DK. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. *Nat Med* 2004; **10**: 161-167 [PMID: 14716308 DOI: 10.1038/nm989]
 - 98 **Huang CW**, Tzeng JN, Chen YJ, Tsai WF, Chen CC, Sun WH. Nociceptors of dorsal root ganglion express proton-sensing G-protein-coupled receptors. *Mol Cell Neurosci* 2007; **36**: 195-210 [PMID: 17720533 DOI: 10.1016/j.mcn.2007.06.010]
 - 99 **Hang LH**, Yang JP, Yin W, Wang LN, Guo F, Ji FH, Shao DH, Xu QN, Wang XY, Zuo JL. Activation of spinal TDAG8 and its downstream PKA signaling pathway contribute to bone cancer pain in rats. *Eur J Neurosci* 2012; **36**: 2107-2117 [PMID: 22515300 DOI: 10.1111/j.1460-9568.2012.08087.x]
 - 100 **Onozawa Y**, Komai T, Oda T. Activation of T cell death-associated gene 8 attenuates inflammation by negatively regulating the function of inflammatory cells. *Eur J Pharmacol* 2011; **654**: 315-319 [PMID: 21238451 DOI: 10.1016/j.ejphar.2011.01.005]
 - 101 **Danese S**, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. *Am J Gastroenterol* 2007; **102**: 174-186 [PMID: 17100967]
 - 102 **Dong L**, Li Z, Leffler NR, Asch AS, Chi JT, Yang LV. Acidosis activation of the proton-sensing GPR4 receptor stimulates vascular endothelial cell inflammatory responses revealed by transcriptome analysis. *PLoS One* 2013; **8**: e61991 [PMID: 23613998 DOI: 10.1371/journal.pone.0061991]
 - 103 **Sufka KJ**, Schomburg FM, Giordano J. Receptor mediation of 5-HT-induced inflammation and nociception in rats. *Pharmacol Biochem Behav* 1992; **41**: 53-56 [PMID: 1531705 DOI: 10.1016/0091-3057(92)90058-N]
 - 104 **Taiwo YO**, Levine JD. Serotonin is a directly-acting hyperalgesic agent in the rat. *Neuroscience* 1992; **48**: 485-490 [PMID: 1534874 DOI: 10.1016/0306-4522(92)90508-Y]

- 105 **Ernberg M**, Lundeberg T, Kopp S. Pain and allodynia/hyperalgesia induced by intramuscular injection of serotonin in patients with fibromyalgia and healthy individuals. *Pain* 2000; **85**: 31-39 [PMID: 10692600]
- 106 **Ernberg M**, Hedenberg-Magnusson B, Kurita H, Kopp S. Effects of local serotonin administration on pain and microcirculation in the human masseter muscle. *J Orofac Pain* 2006; **20**: 241-248 [PMID: 16913434]
- 107 **Millan MJ**. Descending control of pain. *Prog Neurobiol* 2002; **66**: 355-474 [PMID: 12034378 DOI: 10.1016/S0301-0082(02)00099-6]
- 108 **Hoyer D**, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. *Pharmacol Biochem Behav* 2002; **71**: 533-554 [PMID: 11888546 DOI: 10.1016/S0091-3057(01)00746-8]
- 109 **Kayser V**, Elfassi IE, Aubel B, Melfort M, Julius D, Gingrich JA, Hamon M, Bourgoin S. Mechanical, thermal and formalin-induced nociception is differentially altered in 5-HT1A-/-, 5-HT1B-/-, 5-HT2A-/-, 5-HT3A-/- and 5-HTT-/- knock-out male mice. *Pain* 2007; **130**: 235-248 [PMID: 17250964 DOI: 10.1016/j.pain.2006.11.015]
- 110 **Granados-Soto V**, Argüelles CF, Rocha-González HI, Godínez-Chaparro B, Flores-Murrieta FJ, Villalón CM. The role of peripheral 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F serotonergic receptors in the reduction of nociception in rats. *Neuroscience* 2010; **165**: 561-568 [PMID: 19837141 DOI: 10.1016/j.neuroscience.2009.10.020]
- 111 **Lin SY**, Chang WJ, Lin CS, Huang CY, Wang HF, Sun WH. Serotonin receptor 5-HT2B mediates serotonin-induced mechanical hyperalgesia. *J Neurosci* 2011; **31**: 1410-1418 [PMID: 21273425 DOI: 10.1523/JNEUROSCI.4682-10.2011]
- 112 **Cervantes-Durán C**, Vidal-Cantú GC, Barragán-Iglesias P, Pineda-Farías JB, Bravo-Hernández M, Murbartian J, Granados-Soto V. Role of peripheral and spinal 5-HT2B receptors in formalin-induced nociception. *Pharmacol Biochem Behav* 2012; **102**: 30-35 [PMID: 22476011 DOI: 10.1016/j.pbb.2012.03.015]
- 113 **Urtikova N**, Berson N, Van Steenwinckel J, Doly S, Truchetto J, Maroteaux L, Pohl M, Conrath M. Antinociceptive effect of peripheral serotonin 5-HT2B receptor activation on neuropathic pain. *Pain* 2012; **153**: 1320-1331 [PMID: 22525520 DOI: 10.1016/j.pain.2012.03.024]
- 114 **Eschalier A**, Kayser V, Guilbaud G. Influence of a specific 5-HT3 antagonist on carrageenan-induced hyperalgesia in rats. *Pain* 1989; **36**: 249-255 [PMID: 2919105 DOI: 10.1016/0304-3959(89)90030-4]
- 115 **Zeitz KP**, Guy N, Malmberg AB, Dirajlal S, Martin WJ, Sun L, Bonhaus DW, Stucky CL, Julius D, Basbaum AI. The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. *J Neurosci* 2002; **22**: 1010-1019 [PMID: 11826129]
- 116 **Giordano J**, Dyche J. Differential analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse. *Neuropharmacology* 1989; **28**: 423-427 [PMID: 2526302 DOI: 10.1016/0028-3908(89)90040-3]
- 117 **Abbott FV**, Hong Y, Blier P. Activation of 5-HT2A receptors potentiates pain produced by inflammatory mediators. *Neuropharmacology* 1996; **35**: 99-110 [PMID: 8684602 DOI: 10.1016/0028-3908(95)00136-0]
- 118 **Tokunaga A**, Saika M, Senba E. 5-HT2A receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery. *Pain* 1998; **76**: 349-355 [PMID: 9718253 DOI: 10.1016/S0304-3959(98)00066-9]
- 119 **Lloyd DR**, Chen PB, Hargreaves KM. Anti-hyperalgesic effects of anti-serotonergic compounds on serotonin- and capsaicin-evoked thermal hyperalgesia in the rat. *Neuroscience* 2012; **203**: 207-215 [PMID: 22209919 DOI: 10.1016/j.neuroscience.2012.07.004]
- 120 **Wang D**, Chen T, Gao Y, Quirion R, Hong Y. Inhibition of SNL-induced upregulation of CGRP and NPY in the spinal cord and dorsal root ganglia by the 5-HT(2A) receptor antagonist ketanserin in rats. *Pharmacol Biochem Behav* 2012; **101**: 379-386 [PMID: 22342663 DOI: 10.1016/j.pbb.2012.02.004]
- 121 **Rahman W**, Bannister K, Bee LA, Dickenson AH. A pronociceptive role for the 5-HT2 receptor on spinal nociceptive transmission: an in vivo electrophysiological study in the rat. *Brain Res* 2011; **1382**: 29-36 [PMID: 21276431 DOI: 10.1016/j.brainres.2011.01.057]
- 122 **Doak GJ**, Sawynok J. Formalin-induced nociceptive behavior and edema: involvement of multiple peripheral 5-hydroxytryptamine receptor subtypes. *Neuroscience* 1997; **80**: 939-949 [PMID: 9276504 DOI: 10.1016/S0306-4522(97)00066-3]
- 123 **Brenchat A**, Romero L, García M, Pujol M, Burgueño J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zamanillo D, Vela JM. 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice. *Pain* 2009; **141**: 239-247 [PMID: 19118950 DOI: 10.1016/j.pain.2008.11.009]
- 124 **Song Z**, Meyerson BA, Linderöth B. Spinal 5-HT receptors that contribute to the pain-relieving effects of spinal cord stimulation in a rat model of neuropathy. *Pain* 2011; **152**: 1666-1673 [PMID: 21514998 DOI: 10.1016/j.pain.2011.03.012]
- 125 **Narumiya S**, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. *Physiol Rev* 1999; **79**: 1193-1226 [PMID: 10508233]
- 126 **Kawabata A**. Prostaglandin E2 and pain--an update. *Biol Pharm Bull* 2011; **34**: 1170-1173 [PMID: 21804201 DOI: 10.1248/bpb.34.1170]
- 127 **Narumiya S**, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. *J Clin Invest* 2001; **108**: 25-30 [PMID: 11435452 DOI: 10.1172/JCI13455]
- 128 **Wang C**, Li GW, Huang LY. Prostaglandin E2 potentiation of P2X3 receptor mediated currents in dorsal root ganglion neurons. *Mol Pain* 2007; **3**: 22 [PMID: 17692121 DOI: 10.1186/1744-8069-3-22]
- 129 **Sekiguchi F**, Aoki Y, Nakagawa M, Kanaoka D, Nishimoto Y, Tsubota-Matsunami M, Yamanaka R, Yoshida S, Kawabata A. AKAP-dependent sensitization of Ca(v) 3.2 channels via the EP(4) receptor/cAMP pathway mediates PGE(2)-induced mechanical hyperalgesia. *Br J Pharmacol* 2013; **168**: 734-745 [PMID: 22924591 DOI: 10.1111/j.1476-5381.2012.02174.x]
- 130 **England S**, Bevan S, Docherty RJ. PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade. *J Physiol* 1996; **495** (Pt 2): 429-440 [PMID: 8887754]
- 131 **Gold MS**, Levine JD, Correa AM. Modulation of TTX-R INa by PKC and PKA and their role in PGE2-induced sensitization of rat sensory neurons in vitro. *J Neurosci* 1998; **18**: 10345-10355 [PMID: 9852572]
- 132 **Aley KO**, Levine JD. Role of protein kinase A in the maintenance of inflammatory pain. *J Neurosci* 1999; **19**: 2181-2186 [PMID: 10066271]
- 133 **Aley KO**, Messing RO, Mochly-Rosen D, Levine JD. Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C. *J Neurosci* 2000; **20**: 4680-4685 [PMID: 10844037]
- 134 **Parada CA**, Yeh JJ, Reichling DB, Levine JD. Transient attenuation of protein kinase Cepsilon can terminate a chronic hyperalgesic state in the rat. *Neuroscience* 2003; **120**: 219-226 [PMID: 12849754 DOI: 10.1016/S0306-4522(03)00267-7]
- 135 **Ferrari LF**, Bogen O, Alessandri-Haber N, Levine E, Gear RW, Levine JD. Transient decrease in nociceptor GRK2 expression produces long-term enhancement in inflammatory pain. *Neuroscience* 2012; **222**: 392-403 [PMID: 22796071 DOI: 10.1016/j.neuroscience.2012.07.004]
- 136 **Ferrari LF**, Levine E, Levine JD. Role of a novel nociceptor autocrine mechanism in chronic pain. *Eur J Neurosci* 2013; **37**: 1705-1713 [PMID: 23379641 DOI: 10.1111/ejn.12145]

- 137 **Latremoliere A**, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. *J Pain* 2009; **10**: 895-926 [PMID: 19712899 DOI: 10.1016/j.jpain.2009.06.012]
- 138 **Sorkin LS**, Westlund KN, Sluka KA, Dougherty PM, Willis WD. Neural changes in acute arthritis in monkeys. IV. Time-course of amino acid release into the lumbar dorsal horn. *Brain Res Brain Res Rev* 1992; **17**: 39-50 [PMID: 1638274 DOI: 10.1016/0165-0173(92)90005-7]
- 139 **Dougherty PM**, Willis WD. Enhanced responses of spinothalamic tract neurons to excitatory amino acids accompany capsaicin-induced sensitization in the monkey. *J Neurosci* 1992; **12**: 883-894 [PMID: 1545244]
- 140 **Dougherty PM**, Sluka KA, Sorkin LS, Westlund KN, Willis WD. Neural changes in acute arthritis in monkeys. I. Parallel enhancement of responses of spinothalamic tract neurons to mechanical stimulation and excitatory amino acids. *Brain Res Brain Res Rev* 1992; **17**: 1-13 [PMID: 1638273 DOI: 10.1016/0165-0173(92)90002-4]
- 141 **Schaible HG**, Grubb BD, Neugebauer V, Oppmann M. The Effects of NMDA Antagonists on Neuronal Activity in Cat Spinal Cord Evoked by Acute Inflammation in the Knee Joint. *Eur J Neurosci* 1991; **3**: 981-991 [PMID: 12106256 DOI: 10.1111/j.1460-9568.1991.tb00034.x]
- 142 **Dougherty PM**, Palecek J, Paleckova V, Sorkin LS, Willis WD. The role of NMDA and non-NMDA excitatory amino acid receptors in the excitation of primate spinothalamic tract neurons by mechanical, chemical, thermal, and electrical stimuli. *J Neurosci* 1992; **12**: 3025-3041 [PMID: 1353793]
- 143 **Coderre TJ**, Melzack R. Central neural mediators of secondary hyperalgesia following heat injury in rats: neuropeptides and excitatory amino acids. *Neurosci Lett* 1991; **131**: 71-74 [PMID: 1686478 DOI: 10.1016/0304-3940(91)90339-U]
- 144 **Ren K**, Hylden JL, Williams GM, Ruda MA, Dubner R. The effects of a non-competitive NMDA receptor antagonist, MK-801, on behavioral hyperalgesia and dorsal horn neuronal activity in rats with unilateral inflammation. *Pain* 1992; **50**: 331-344 [PMID: 1454389 DOI: 10.1016/0304-3959(92)90039-E]
- 145 **Dubner R**, Ruda MA. Activity-dependent neuronal plasticity following tissue injury and inflammation. *Trends Neurosci* 1992; **15**: 96-103 [PMID: 1373925 DOI: 10.1016/0166-2236(92)90019-5]
- 146 **Guo W**, Zou S, Guan Y, Ikeda T, Tal M, Dubner R, Ren K. Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia. *J Neurosci* 2002; **22**: 6208-6217 [PMID: 12122079]
- 147 **Caudle RM**, Perez FM, Del Valle-Pinero AY, Iadarola MJ. Spinal cord NR1 serine phosphorylation and NR2B subunit suppression following peripheral inflammation. *Mol Pain* 2005; **1**: 25 [PMID: 16137337 DOI: 10.1186/1744-8069-1-25]
- 148 **Ji RR**, Gereau RW, Malcangio M, Strichartz GR. MAP kinase and pain. *Brain Res Rev* 2009; **60**: 135-148 [PMID: 19150373 DOI: 10.1016/j.brainresrev.2008.12.011]
- 149 **Karim F**, Hu HJ, Adwanikar H, Kaplan D, Gereau RW. Impaired inflammatory pain and thermal hyperalgesia in mice expressing neuron-specific dominant negative mitogen activated protein kinase kinase (MEK). *Mol Pain* 2006; **2**: 2 [PMID: 16412244 DOI: 10.1186/1744-8069-2-2]
- 150 **Mannion RJ**, Costigan M, Decosterd I, Amaya F, Ma QP, Holstege JC, Ji RR, Acheson A, Lindsay RM, Wilkinson GA, Woolf CJ. Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity. *Proc Natl Acad Sci USA* 1999; **96**: 9385-9390 [PMID: 10430952 DOI: 10.1073/pnas.96.16.9385]
- 151 **Stubhaug A**, Breivik H, Eide PK, Kreunen M, Foss A. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. *Acta Anaesthesiol Scand* 1997; **41**: 1124-1132 [PMID: 9366932 DOI: 10.1111/j.1399-6576.1997.tb04854.x]

P- Reviewer: Yousef AA **S- Editor:** Song XX **L- Editor:** A
E- Editor: Wang CH





百世登
Baishideng®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

